18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and Rv1733c....
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Tuberculosis vaccine: Phase II started

Intercell said Statens Serum Institut (Copenhagen, Denmark) began a double-blind, South African and Tanzanian Phase II trial to evaluate 2 doses of H1IC in HIV-infected patients. The European and Developing Countries Clinical Trials Partnership...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

Protecting against latent TB

A team of EU and U.S. researchers has created a subunit vaccine based on three Mycobacterium tuberculosis antigens and shown that it protects healthy mice from tuberculosis and prevents reactivation of disease in mouse models...
08:00 , Feb 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) Mycobacterium tuberculosis Rv2660c hypothetical protein (Rv2660c); M. tuberculosis secreted antigen...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease ...
08:00 , Mar 5, 2009 |  BC Innovations  |  Targets & Mechanisms

Subunit boost for TB vaccines

A long-term study in macaques by GlaxoSmithKline plcand collaborators bolsters the case for using a subunit tuberculosis vaccine to boost the effects of the only marketed TB prophylactic-bacille Calmette-Guérin (BCG).1 Ongoing Phase I and Phase...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

HyVac4: Phase I started

ICLL began a placebo-controlled, Swedish Phase I trial of HyVac4 in 64 individuals vaccinated with Bacillus of Calmette and Guerin (BCG) vaccine. ICLL is co-developing HyVac4 with Aeras Global TB Vaccine Foundation (Rockville, Md.). Intercell...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

Tuberculosis: Preliminary Phase I data

Preliminary data from an open-label, Dutch Phase I trial in 36 healthy volunteers showed that ICLL's TB vaccine was safe and stimulated a strong immunogenic T cell response. Intercell AG (VSE:ICLL), Vienna, Austria   Product: Tuberculosis...